Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Autism Spectrum Disorder (ASD)

Ibogaine for Autism Spectrum Disorder (ASD)

1 paper and 0 clinical trials exploring ibogaine as a treatment for autism spectrum disorder (asd).

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
IndicationApproximately 1 in 160 children worldwide.

Autism Spectrum Disorder (ASD)

Research into the use of psychedelics for treating Autism Spectrum Disorder (ASD) is limited but gaining traction, with preliminary studies suggesting potential therapeutic benefits, particularly for associated social anxiety. Notable figures in this emerging field, such as Alicia Danforth and Charles Grob, are advocating for further exploration of psychedelics in ASD treatment.

Full Autism Spectrum Disorder (ASD) profile

Academic Research

1 paper
Open Accessindividual

Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport

This study investigated serotonin transporter (SERT) complexes with ibogaine to illustrate structure-based mechanisms for transport in serotonin transporter (SERT). The investigation reported that cryo-electron microscopy structures of SERT-ibogaine complexes captured in outward-open, closed and inward-open conformations with ibogaine binding to the central binding site, and the closing extracellular gate with movements of TMs 1b and 6a. The intracellular gate opening had a hinge-like movement of TM1a and the partial unwinding of TM5 that together built a permeation pathway enabling substrate and ion diffusion to the cytoplasm. These structures show the structural rearrangements which occur from the outward-open to inward-open conformations, and give an important insight into the working mechanism of neurotransmitter transport and ibogaine inhibition.

Published
April 24, 2019
Journal
Nature
Authors
Coleman, J. A., Yang, D., Zhao, Z., Wen, P. C., Yoshioka, C., Gouaux, E.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ibogaine and Autism Spectrum Disorder (ASD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ibogaine papers Search all Autism Spectrum Disorder (ASD) trials Full Ibogaine profile Full Autism Spectrum Disorder (ASD) profile